Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients

References

• Wang QL, Xie SH, Wahlin K, et al. Global time trends in the incidence of esophageal squamous cell carcinoma. Clin Epidemiol. 2018;10:717–728. doi: 10.2147/CLEP.S166078.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou K, Yang L, et al. Racial differences in esophageal squamous cell carcinoma: incidence and molecular features. Biomed Res Int. 2017;2017:1204082. doi: 10.1155/2017/1204082.
   PubMed Web of Science ®Google Scholar
• Uhlenhopp DJ, Then EO, Sunkara T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010–1021. doi: 10.1007/s12328-020-01237-x.
   PubMed Web of Science ®Google Scholar
• Sunde B, Lindblad M, Malmström M, et al. Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study from the Swedish National Registry for Oesophageal and Gastric Cancer. BMC Cancer. 2021;21(1):1277. doi: 10.1186/s12885-021-09007-9.
   PubMed Web of Science ®Google Scholar
• Davis LE, Gupta V, Allen-Ayodabo C, et al. Patient-reported symptoms following diagnosis in esophagus cancer patients treated with palliative intent. Dis Esophagus. 2020;33(8):doz108. doi: 10.1093/dote/doz108.
   PubMed Web of Science ®Google Scholar
• Ter Veer E, van Kleef JJ, Schokker S, et al. Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: a systematic review and meta-analysis. Eur J Cancer. 2018;103:214–226. doi: 10.1016/j.ejca.2018.07.132.
   PubMed Web of Science ®Google Scholar
• van Kleef JJ, Dijksterhuis WPM, van den Boorn HG, et al. Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study. Gastric Cancer. 2021;24(6):1203–1212. doi: 10.1007/s10120-021-01209-1.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Kato K, Okada M, et al. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). Esophagus. 2021;18(1):90–99. doi: 10.1007/s10388-020-00794-x.
   PubMed Web of Science ®Google Scholar
• Adenis A, Kulkarni AS, Girotto GC, et al. Impact of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer on health-related quality of life in KEYNOTE-181. J Clin Oncol. 2022;40(4):382–391. doi: 10.1200/JCO.21.00601.
   PubMed Web of Science ®Google Scholar
• Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832–842. doi: 10.1016/S1470-2045(20)30110-8.
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. doi: 10.1016/S1470-2045(19)30626-6.
   PubMed Web of Science ®Google Scholar
• Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40(26):3065–3076. doi: 10.1200/JCO.21.01926.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kato K, Ajani J, et al. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open. 2022;7(4):100517. doi: 10.1016/j.esmoop.2022.100517.
   PubMed Web of Science ®Google Scholar
• Wang J, Yu X, Barnes G, et al. The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: results from a phase 3 randomized clinical trial. Cancer Treat Res Commun. 2021;30:100501. doi: 10.1016/j.ctarc.2021.100501.
   PubMedGoogle Scholar
• Lu S, Yu Y, Barnes G, et al. Examining the impact of tislelizumab added to chemotherapy on health-related quality-of-life outcomes in previously untreated patients with nonsquamous non-small cell lung cancer. Cancer J. 2022;28(2):96–104. doi: 10.1097/PPO.0000000000000583.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
   PubMed Web of Science ®Google Scholar
• Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39(10):1384–1394. doi: 10.1016/s0959-8049(03)00270-3.
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and Progression-Free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–925. doi: 10.1001/jama.2021.12836.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims; [Published 2009. Cited 2022 Dec 1]. Available from: https://www.fda.gov/media/77832/download.
   Google Scholar